Table 2
Open in new tab

Data collection besides laboratory test results

CharacterisitcsFrench-speaking BelgiumCzech RepublicaFinlandFranceNorwayRomaniaaSwedena
MethodsManual data entry in web platformElectronic automated data extractionManual data entry in web platformManual data entry in web platformPaper formsManual data entry in web platformManual data entry in web platform (but patient-reported outcomes are entered by patients online)
Patient identifierFrench-Belgian ESRD Registry identification numberNational identification number and Registry identification numberNational insurance numberREIN identification numberNational identification numberNational identification numberNational insurance number
Follow-up schemeEvery year or at change of CKD stageEvery yearTBDAt 3 months after inclusion; thereafter every year. For bundle payment every 6 monthsEvery yearAt each patient visitEvery year; <20 mL/min/1.73 m2 every 6 months
Patient characteristics at inclusion
 Demographics+++++++
 Education level−−TBD+−−−
 Living conditions−−TBD+−−−
 PRD+++++++
 Date first visit to nephrologist++TBD+−−+
 Date first eGFR <15 mL/min/1.73 m2−−TBD++−+
 Comorbidities++TBD++++
 Height++TBD++++
 Weight++TBD++++
 Blood pressure−+TBD−+−+
 Planned care (KRT versus non-KRT versus not fixed/discussed)−−TBD++−−
Patient characteristics during follow-up
 Living conditions−−TBD+−−−
 Comorbidities−+TBD+b+++
 Height−+TBD−−++
 Weight−+TBD−+++
 Blood pressure−+TBD−+−+
 Planned care (KRT versus non-KRT versus not fixed/discussed)−−TBD+−−+
Treatment at inclusion
 Antihypertensives−+TBD−+++
 Antidiabetics−−TBD−++−
 Diuretics−+TBD−−++
 ESA−+TBD−+++
 Iron−−TBD−−++
 Ketoanalogues−+TBD−−+−
 Phosphate binders−+TBD−+++
 Protein intake recommendation−−TBD−−+−
 Statins−+TBD−+++
 Vitamin D analogues−+TBD−+++
 Vit D supplements−+TBD−−++
Treatment during follow-up
 Antihypertensives−+TBD−+++
 Antidiabetics−−TBD−++−
 Diuretics−−TBD−−++
 ESA−+TBD−+++
 Iron−−TBD−−++
 Ketoanalogues−+TBD−−+−
 Phosphate binders−+TBD−+++
 Protein intake recommendation−−TBD−−+−
 Statins−−TBD−+++
 Vitamin D analogues−+TBD−+++
 Vitamin D supplements−+TBD−−++
Outcomes
 CKD progression+++++++
 Acute kidney injury−−TBD−−+−
 Dialysis++TBD++++
 Transplant waiting list−+TBD++−−
 Transplantation++TBD++++
 Patient-reported outcomes−−TBD−−−+
 Death++TBD++++
 Cause of death++TBD++−+
CharacterisitcsFrench-speaking BelgiumCzech RepublicaFinlandFranceNorwayRomaniaaSwedena
MethodsManual data entry in web platformElectronic automated data extractionManual data entry in web platformManual data entry in web platformPaper formsManual data entry in web platformManual data entry in web platform (but patient-reported outcomes are entered by patients online)
Patient identifierFrench-Belgian ESRD Registry identification numberNational identification number and Registry identification numberNational insurance numberREIN identification numberNational identification numberNational identification numberNational insurance number
Follow-up schemeEvery year or at change of CKD stageEvery yearTBDAt 3 months after inclusion; thereafter every year. For bundle payment every 6 monthsEvery yearAt each patient visitEvery year; <20 mL/min/1.73 m2 every 6 months
Patient characteristics at inclusion
 Demographics+++++++
 Education level−−TBD+−−−
 Living conditions−−TBD+−−−
 PRD+++++++
 Date first visit to nephrologist++TBD+−−+
 Date first eGFR <15 mL/min/1.73 m2−−TBD++−+
 Comorbidities++TBD++++
 Height++TBD++++
 Weight++TBD++++
 Blood pressure−+TBD−+−+
 Planned care (KRT versus non-KRT versus not fixed/discussed)−−TBD++−−
Patient characteristics during follow-up
 Living conditions−−TBD+−−−
 Comorbidities−+TBD+b+++
 Height−+TBD−−++
 Weight−+TBD−+++
 Blood pressure−+TBD−+−+
 Planned care (KRT versus non-KRT versus not fixed/discussed)−−TBD+−−+
Treatment at inclusion
 Antihypertensives−+TBD−+++
 Antidiabetics−−TBD−++−
 Diuretics−+TBD−−++
 ESA−+TBD−+++
 Iron−−TBD−−++
 Ketoanalogues−+TBD−−+−
 Phosphate binders−+TBD−+++
 Protein intake recommendation−−TBD−−+−
 Statins−+TBD−+++
 Vitamin D analogues−+TBD−+++
 Vit D supplements−+TBD−−++
Treatment during follow-up
 Antihypertensives−+TBD−+++
 Antidiabetics−−TBD−++−
 Diuretics−−TBD−−++
 ESA−+TBD−+++
 Iron−−TBD−−++
 Ketoanalogues−+TBD−−+−
 Phosphate binders−+TBD−+++
 Protein intake recommendation−−TBD−−+−
 Statins−−TBD−+++
 Vitamin D analogues−+TBD−+++
 Vitamin D supplements−+TBD−−++
Outcomes
 CKD progression+++++++
 Acute kidney injury−−TBD−−+−
 Dialysis++TBD++++
 Transplant waiting list−+TBD++−−
 Transplantation++TBD++++
 Patient-reported outcomes−−TBD−−−+
 Death++TBD++++
 Cause of death++TBD++−+
a

Collection of medications data through Anatomical Therapeutic Chemical or similar codes.

b

For bundle payment.+, positive; −, negative; TBD, to be determizned.

Table 2
Open in new tab

Data collection besides laboratory test results

CharacterisitcsFrench-speaking BelgiumCzech RepublicaFinlandFranceNorwayRomaniaaSwedena
MethodsManual data entry in web platformElectronic automated data extractionManual data entry in web platformManual data entry in web platformPaper formsManual data entry in web platformManual data entry in web platform (but patient-reported outcomes are entered by patients online)
Patient identifierFrench-Belgian ESRD Registry identification numberNational identification number and Registry identification numberNational insurance numberREIN identification numberNational identification numberNational identification numberNational insurance number
Follow-up schemeEvery year or at change of CKD stageEvery yearTBDAt 3 months after inclusion; thereafter every year. For bundle payment every 6 monthsEvery yearAt each patient visitEvery year; <20 mL/min/1.73 m2 every 6 months
Patient characteristics at inclusion
 Demographics+++++++
 Education level−−TBD+−−−
 Living conditions−−TBD+−−−
 PRD+++++++
 Date first visit to nephrologist++TBD+−−+
 Date first eGFR <15 mL/min/1.73 m2−−TBD++−+
 Comorbidities++TBD++++
 Height++TBD++++
 Weight++TBD++++
 Blood pressure−+TBD−+−+
 Planned care (KRT versus non-KRT versus not fixed/discussed)−−TBD++−−
Patient characteristics during follow-up
 Living conditions−−TBD+−−−
 Comorbidities−+TBD+b+++
 Height−+TBD−−++
 Weight−+TBD−+++
 Blood pressure−+TBD−+−+
 Planned care (KRT versus non-KRT versus not fixed/discussed)−−TBD+−−+
Treatment at inclusion
 Antihypertensives−+TBD−+++
 Antidiabetics−−TBD−++−
 Diuretics−+TBD−−++
 ESA−+TBD−+++
 Iron−−TBD−−++
 Ketoanalogues−+TBD−−+−
 Phosphate binders−+TBD−+++
 Protein intake recommendation−−TBD−−+−
 Statins−+TBD−+++
 Vitamin D analogues−+TBD−+++
 Vit D supplements−+TBD−−++
Treatment during follow-up
 Antihypertensives−+TBD−+++
 Antidiabetics−−TBD−++−
 Diuretics−−TBD−−++
 ESA−+TBD−+++
 Iron−−TBD−−++
 Ketoanalogues−+TBD−−+−
 Phosphate binders−+TBD−+++
 Protein intake recommendation−−TBD−−+−
 Statins−−TBD−+++
 Vitamin D analogues−+TBD−+++
 Vitamin D supplements−+TBD−−++
Outcomes
 CKD progression+++++++
 Acute kidney injury−−TBD−−+−
 Dialysis++TBD++++
 Transplant waiting list−+TBD++−−
 Transplantation++TBD++++
 Patient-reported outcomes−−TBD−−−+
 Death++TBD++++
 Cause of death++TBD++−+
CharacterisitcsFrench-speaking BelgiumCzech RepublicaFinlandFranceNorwayRomaniaaSwedena
MethodsManual data entry in web platformElectronic automated data extractionManual data entry in web platformManual data entry in web platformPaper formsManual data entry in web platformManual data entry in web platform (but patient-reported outcomes are entered by patients online)
Patient identifierFrench-Belgian ESRD Registry identification numberNational identification number and Registry identification numberNational insurance numberREIN identification numberNational identification numberNational identification numberNational insurance number
Follow-up schemeEvery year or at change of CKD stageEvery yearTBDAt 3 months after inclusion; thereafter every year. For bundle payment every 6 monthsEvery yearAt each patient visitEvery year; <20 mL/min/1.73 m2 every 6 months
Patient characteristics at inclusion
 Demographics+++++++
 Education level−−TBD+−−−
 Living conditions−−TBD+−−−
 PRD+++++++
 Date first visit to nephrologist++TBD+−−+
 Date first eGFR <15 mL/min/1.73 m2−−TBD++−+
 Comorbidities++TBD++++
 Height++TBD++++
 Weight++TBD++++
 Blood pressure−+TBD−+−+
 Planned care (KRT versus non-KRT versus not fixed/discussed)−−TBD++−−
Patient characteristics during follow-up
 Living conditions−−TBD+−−−
 Comorbidities−+TBD+b+++
 Height−+TBD−−++
 Weight−+TBD−+++
 Blood pressure−+TBD−+−+
 Planned care (KRT versus non-KRT versus not fixed/discussed)−−TBD+−−+
Treatment at inclusion
 Antihypertensives−+TBD−+++
 Antidiabetics−−TBD−++−
 Diuretics−+TBD−−++
 ESA−+TBD−+++
 Iron−−TBD−−++
 Ketoanalogues−+TBD−−+−
 Phosphate binders−+TBD−+++
 Protein intake recommendation−−TBD−−+−
 Statins−+TBD−+++
 Vitamin D analogues−+TBD−+++
 Vit D supplements−+TBD−−++
Treatment during follow-up
 Antihypertensives−+TBD−+++
 Antidiabetics−−TBD−++−
 Diuretics−−TBD−−++
 ESA−+TBD−+++
 Iron−−TBD−−++
 Ketoanalogues−+TBD−−+−
 Phosphate binders−+TBD−+++
 Protein intake recommendation−−TBD−−+−
 Statins−−TBD−+++
 Vitamin D analogues−+TBD−+++
 Vitamin D supplements−+TBD−−++
Outcomes
 CKD progression+++++++
 Acute kidney injury−−TBD−−+−
 Dialysis++TBD++++
 Transplant waiting list−+TBD++−−
 Transplantation++TBD++++
 Patient-reported outcomes−−TBD−−−+
 Death++TBD++++
 Cause of death++TBD++−+
a

Collection of medications data through Anatomical Therapeutic Chemical or similar codes.

b

For bundle payment.+, positive; −, negative; TBD, to be determizned.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close